Cost-effectiveness of talazoparib for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US
Article in Scientific Reports (June 2024)
The most recent citing publications are shown below. View all 4 publications that cite this research output on Dimensions.
Cost-Effectiveness Analysis of talazoparib Maintenance Treatment for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US
Preprint in Research Square (October 2023)
BRCA Mutations—The Achilles Heel of Breast, Ovarian and Other Epithelial Cancers
Article in International Journal of Molecular Sciences (March 2023)